According to the Insight database, between June 23 and June 25, AstraZeneca intensively initiated six Phase III clinical trials for Elecoglipron, with indications covering obesity and type 2 diabetes.
Elecoglipron (development codes: ECC5004 / AZD5004) is a once-daily, low-dose, small-molecule GLP-1 receptor agonist developed by Eccogene. In November 2023, AstraZeneca obtained exclusive rights from Eccogene to develop and commercialize the drug for all indications in all countries and regions outside of China (in China, the drug will be co-developed and co-commercialized by Eccogene and AstraZeneca). Under the terms of the agreement, Eccogene will receive an upfront payment of $185 million, with the potential to receive up to $1.825 billion in clinical, regulatory, and commercial milestone payments, as well as tiered royalties on net sales of the product.
At the 2026 ADA Annual Meeting, AstraZeneca presented positive results from the VISTA and SOLSTICE Phase IIb studies of Elecoglipron. VISTA was a Phase IIb randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of Elecoglipron in adult patients with obesity or overweight and at least one weight-related comorbidity. The study results showed that at 26 weeks of treatment with Elecoglipron (75 mg), the mean weight loss was 10.5%, compared with 0.6% in the placebo group. Moreover, weight loss in Elecoglipron-treated subjects did not plateau, and by 36 weeks, the weight loss in the 75 mg group reached 11.8%, compared with 0.3% in the placebo group.
SOLSTICE was a Phase IIb randomized, double-blind, placebo-controlled and open-label active-controlled study designed to evaluate the efficacy, safety, and tolerability of Elecoglipron in adults with type 2 diabetes. Data showed that in adults with type 2 diabetes treated with Elecoglipron (75 mg), the mean reduction in HbA1c from baseline at Week 26 was 1.9%, compared with 0.2% in the placebo group. In addition, Elecoglipron (75 mg) demonstrated a clinically meaningful weight reduction at Week 26, with a mean reduction of 7.7% compared with 1.7% in the placebo group. In terms of safety, the safety profile of Elecoglipron was consistent with the GLP-1 RA drug class. Adverse events were primarily gastrointestinal in nature and were mostly mild to moderate.
Buy AZD5004 from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
